English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Autologous hematopoietic stem cell transplantation (auto-HSCT) is the standard treatment option for multiple myeloma (MM) and relapsed non-Hodgkin’s lymphoma (NHL) patients.1, 2, 3 Granulocyte colony stimulating factor (G-CSF) combined with high-dose chemotherapy is a frequently used mobilization approach.2 Chemo-mobilization success depends on the patient’s age, apheresis timing, chemotherapy and immunomodulatory regimens as well as chemotherapy-related adverse events (AEs).3 Mobilization failure leads to remobilization, which negatively impacts clinical outcomes and healthcare costs.4

Cyclophosphamide vs salvage chemotherapy plus G-CSF as chemo-mobilization in Asian patients undergoing autologous hematopoietic stem cell transplant